Next 10 |
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-22 11:00:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity Eli Lilly And Alzheimer's Disease: The Paucity Of Progress ResMed, Philips under pressur...
2024-06-19 12:30:39 ET Summary In recent months, Eli Lilly has continued to delight investors with growth in its share price. Strong sales of the company's diabetes franchise, coupled with progress in the development of tirzepatide, have helped its market capitalization double ove...
2024-06-17 21:24:55 ET Summary Paulson's 13F portfolio value increased to ~$1.45B with 18 securities, top positions include Madrigal Pharma and Bausch Health. John Paulson is known for his leveraged bets against the real-estate bubble, and converted to a Family Office structure in...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...
2024-06-15 09:45:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is in a position that most other biotechs envy. Its first medicine just hit the market, sales are due to start rolling in, and there aren't any other companies that can slow it down -- for now, that is. By mid-2027, ...
2024-06-12 10:16:29 ET Summary Madrigal Pharmaceuticals, Inc. stock has enjoyed peaks and troughs as it has pursued its path to the approval of NASH drug Rezdiffra. The company's stock was buoyant yesterday, enjoying a 15% gain after Wolfe Research initiated positive coverage. ...
2024-06-11 13:49:24 ET More on Akero Therapeutics Akero Therapeutics' EFX Data Warrants Caution Seeking Alpha’s Quant Rating on Akero Therapeutics Historical earnings data for Akero Therapeutics Financial information for Akero Therapeutics Re...
2024-06-11 13:28:02 ET More on Madrigal Pharmaceuticals Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label Madriga...
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is one of today's top gainers. The company's shares have moved 10.99% on the day to $282.88. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for ...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...
2024-06-15 09:45:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is in a position that most other biotechs envy. Its first medicine just hit the market, sales are due to start rolling in, and there aren't any other companies that can slow it down -- for now, that is. By mid-2027, ...